Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
88 studies found for:    vaccine niaid | Open Studies
Show Display Options
Rank Status Study
1 Recruiting A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-borne Encephalitis (TBE) for NIAID Workers Manipulating Tick Borne Encephalitis Virus (TBEV) in the Laboratory
Conditions: Tick-Borne Encephalitis;   Encephalitis, Tick-Borne;   Tick-Borne Disease;   Glycoprotein E, Flavivirus;   NSI Protein, Flavivirus
Intervention: Biological: FSME-IMMUN 0.5ml Baxter
2 Recruiting Evaluating the Safety of and Immune Response to a Dengue Vaccine (TV003) in Healthy Adults, Adolescents, and Children in Thailand
Condition: Dengue
Interventions: Biological: TV003;   Biological: Placebo for TV003
3 Recruiting Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products
Condition: Healthy Volunteers
Intervention:
4 Recruiting Screening Volunteers for Clinical Trials
Condition: Human Health
Intervention:
5 Recruiting Volunteer Screening for Vaccine and Antivirals Clinical Trials
Condition: Healthy Volunteer
Intervention:
6 Recruiting Safety and Immunogenicity of a Zika Virus DNA Vaccine, VRC-ZKADNA085-00-VP, in Healthy Adults
Conditions: Prevention of Zika Infection;   Zika-Specific Immune Response
Intervention: Biological: VRC-ZKADNA085-00-VP
7 Not yet recruiting Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure
Condition: Healthy Volunteers
Intervention: Drug: rVSVdeltaG-ZEBOV GP (2X 107 pfu/mL)
8 Recruiting Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers
Conditions: Healthy Volunteer;   HIV Vaccine
Interventions: Biological: Ad4-mgag;   Biological: Ad4-EnvC150
9 Recruiting Trial for Safety and Immunogenicity of a Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults
Condition: Chikungunya Virus Infection
Interventions: Biological: VRC-CHKVLP059-00-VP;   Other: VRC-PBSPLA043-00-VP
10 Recruiting Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates
Condition: Malaria
Intervention:
11 Recruiting Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge
Condition: Malaria
Intervention:
12 Recruiting Antibody Production in Immune Disorders
Condition: Immunologic Disease
Intervention:
13 Recruiting Apheresis and Specimen Collection Procedures to Obtain Plasma, Peripheral Blood Mononuclear Cells (PBMCs) and Other Specimens for Research Studies
Condition: Blood Component Removal
Intervention:
14 Recruiting A Phase I Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers
Condition: Yellow Fever
Interventions: Biological: MVA Smallpox Vaccine;   Biological: YF Vax 17D Strain;   Drug: ISA-720;   Biological: MVA-BN Yellow Fever Vaccine;   Other: Placebo
15 Recruiting Evaluating the Safety and Protective Efficacy of a Single Dose of a Trivalent Live Attenuated Dengue Vaccine to Protect Against Infection With DENV-2
Condition: Dengue
Interventions: Biological: Recombinant live attenuated trivalent dengue vaccine;   Biological: Placebo;   Biological: rDEN2Δ30-7169 vaccine
16 Recruiting A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine
Condition: Avian Influenza
Interventions: Drug: MF59;   Biological: Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca;   Biological: Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
17 Recruiting Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV ΔNS2 Δ1313 I1314L Vaccine;   Biological: Placebo (1x Leibovitz L-15 medium)
18 Recruiting Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV LID ΔM2-2 1030s vaccine;   Biological: Placebo
19 Not yet recruiting Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV LID cp ΔM2-2 Vaccine;   Biological: Placebo
20 Recruiting Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: D46cpΔM2-2 vaccine;   Biological: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years